Chapter 231: The Cover

September 25th, 2027.

The sun had just risen over New York City, but the headquarters of Aegis Pharmaceuticals was already buzzing with activity. Reporters from CNN, The New York Times, and other major media outlets had gathered outside, eager to cover the latest developments in the high-stakes saga between Aegis Pharmaceuticals and Reyes Corporation.

Cameras flashed and microphones were thrust forward as Elena Skies, CEO of Aegis Pharmaceuticals, emerged from the building. She paused at the entrance, her composed demeanor betraying none of the stress she had been under in recent weeks.

"Ms. Skies, over here!" shouted a reporter from CNN. "What do you have to say about the recent accusations against Aegis Pharmaceuticals?"

Elena took a deep breath and stepped up to the microphone. "Good morning. I'd like to address the recent reports and clarify our position. The documents that were leaked are fake and fabricated. They do not represent the actions or intentions of Aegis Pharmaceuticals."

A journalist from The New York Times quickly followed up. "Ms. Skies, are you saying there is no truth to the allegations that Aegis Pharmaceuticals attempted to steal proprietary technology from Reyes Corporation?"

"That is correct," Elena replied firmly. "We have been in communication with Reyes Corporation, and they agree that the documents are falsified. Both of our companies are committed to resolving this matter amicably and ensuring that the truth comes to light."

"Can you provide any details about your recent meeting with Michael Reyes?" asked a reporter from Reuters.

Elena nodded. "Mr. Reyes and I have had constructive discussions. We are both focused on moving forward and strengthening our collaboration. Our primary goal is to maintain the integrity and reputation of both companies."

"Are there any legal actions being taken against the perpetrators of this alleged fabrication?" inquired a journalist from the Wall Street Journal.

"Our legal teams are currently investigating the source of the fabricated documents," Elena said. "We are determined to hold those responsible accountable for their actions."

A final question came from a CNBC reporter. "What steps are you taking to ensure the security of your company's sensitive information going forward?"

Elena looked directly at the camera. "We are implementing enhanced security measures to protect our data and prevent any future breaches. Aegis Pharmaceuticals remains committed to innovation and excellence, and we will not let this incident deter us from our mission."

A reporter from Rappler then asked, "What measures are you taking to ensure the security and integrity of your company's information moving forward?"

Michael responded, "We are implementing advanced security protocols and enhancing our cybersecurity measures. We are also conducting thorough internal audits to ensure that all sensitive information is protected. Both companies are committed to maintaining the highest standards of security."

A journalist from the Philippine Star asked, "Mr. Reyes, any future collaboration with Aegis Pharmaceuticals?"

"Well, given that we are both in the medical field with a goal and vision to save as many lives as possible through advanced technology and innovative solutions, future collaborations are definitely on the table," Michael replied. "We are exploring several joint projects that could potentially revolutionize healthcare and improve patient outcomes."

Seeing that no one was raising their hands to ask more questions, Michael prepared to wrap up the press conference.

"Thank you all for your questions and for your continued interest in the developments between Reyes Corporation and Aegis Pharmaceuticals. We are committed to transparency and will keep you informed of any further updates. Have a great day."

Michael stepped away from the podium, and the reporters began to disperse. Juliet approached him with a satisfied smile.

"That went well," she said.

Michael nodded. "Yes, it did. Now, let's focus on moving forward. Particularly, let's focus on that VR technology we plan on introducing to the world in the future."

"About that, the board of directors is keen on releasing a teaser for the VR technology," Juliet said.

Michael shook his head. "The teaser can wait. We need to build the necessary infrastructure to support VR games worldwide first. Without that foundation, any teaser would be premature and potentially damaging."

Juliet nodded, taking notes. "Understood. We'll focus on the infrastructure. What are your immediate priorities?"

"Let's create a scheme."